MX2007004250A - Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos. - Google Patents
Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos.Info
- Publication number
- MX2007004250A MX2007004250A MX2007004250A MX2007004250A MX2007004250A MX 2007004250 A MX2007004250 A MX 2007004250A MX 2007004250 A MX2007004250 A MX 2007004250A MX 2007004250 A MX2007004250 A MX 2007004250A MX 2007004250 A MX2007004250 A MX 2007004250A
- Authority
- MX
- Mexico
- Prior art keywords
- lower alkyl
- halogen
- treatment
- substituted
- cycloalkyl
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 title 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical class N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
La presente invencion se relaciona con el uso de derivados imidazo [l, 5-a] [1, 2,4] triazolo [l,5-d][l14]benzodiazepina substituida de la siguiente formula (1); en donde RI es halogeno, alquilo inferior, alquinilo inferior, cicloalquilo, alcoxi inferior, OCF3, -NHR, -NHC(O)R o -NHS02R; R2 es hidrogeno, metilo o arilo, el cual es no-substituido o substituido por uno o dos sustituyentes, seleccionados del grupo que consiste de halogeno o alcoxi inferior; R3 es hidrogeno, alquilo inferior, alquenilo inferior, cicloalquilo, un alcoxi inferior, -O (CH2)n+1-O-alquil inferior, - (CH2)n,- aril el cual es substituido opcionalmente por un alquilo inferior o un halogeno, heteroarilo -NHR, -NR2, en donde R2 puede ser el mismo o diferente, o es -NHCH2C=CH, o pirrolidina-1-ona; R es hidrogeno, alquilo inferior, alquilo inferior substituido por halogeno, heteroarilo, -(CH2)nO-alquil inferior, -NH-alquil inferior, cicloalquilo o arilo, n es 0, 1, 2 o 3; y con sus sales de adicion de acido farmaceuticamente aceptables para la manufactura de los medicamentos para el tratamiento para una mejora cognoscitiva o para el tratamiento de desordenes cognitivos, de ansiedad o de esquizofrenia. La indicacion mas preferida es la enfermedad de Alzheimer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04105000 | 2004-10-12 | ||
| PCT/EP2005/010655 WO2006040038A1 (en) | 2004-10-12 | 2005-10-04 | Imidazo [1, 5-a]triazolo[1, 5-d]benzodiazepine derivatives for the treatment of cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007004250A true MX2007004250A (es) | 2007-06-12 |
Family
ID=35427599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007004250A MX2007004250A (es) | 2004-10-12 | 2005-10-04 | Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7671048B2 (es) |
| EP (1) | EP1809297B1 (es) |
| JP (1) | JP5117192B2 (es) |
| KR (1) | KR100869388B1 (es) |
| CN (1) | CN101039678B (es) |
| AT (1) | ATE402707T1 (es) |
| AU (1) | AU2005293820B2 (es) |
| BR (1) | BRPI0517412A (es) |
| CA (1) | CA2581918A1 (es) |
| DE (1) | DE602005008633D1 (es) |
| ES (1) | ES2312022T3 (es) |
| MX (1) | MX2007004250A (es) |
| RU (1) | RU2007112675A (es) |
| WO (1) | WO2006040038A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4885967B2 (ja) * | 2005-10-11 | 2012-02-29 | エフ．ホフマン−ラ ロシュ アーゲー | イミダゾベンゾジアゼピン誘導体 |
| US10994357B2 (en) * | 2006-12-20 | 2021-05-04 | Lincoln Global, Inc. | System and method for creating or modifying a welding sequence |
| US8538675B2 (en) | 2009-06-01 | 2013-09-17 | Raytheon Company | Non-kinematic behavioral mapping |
| EA201390710A1 (ru) * | 2010-11-15 | 2013-12-30 | Эйджинбайо, Инк. | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения |
| EA027840B1 (ru) | 2010-11-15 | 2017-09-29 | Эйджинбайо, Инк. | Производные пиридазина, композиции и способы лечения когнитивного нарушения |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| JP6883988B2 (ja) | 2013-12-20 | 2021-06-09 | エージンバイオ， インコーポレイテッド | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
| IL256354B (en) * | 2015-06-19 | 2022-09-01 | Agenebio Inc | Benzodiazepine derivatives, compositions, and uses thereof for treating cognitive impairment |
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| AU2018275686B2 (en) * | 2017-06-02 | 2024-02-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
| MX2020013927A (es) | 2018-06-19 | 2021-03-02 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo. |
| CN111606926B (zh) * | 2020-05-13 | 2021-10-15 | 大连理工大学 | 一种苯并咪唑[1,3]氮硫杂卓类化合物的制备方法 |
| CN112979658B (zh) * | 2021-02-22 | 2022-05-31 | 南湖实验室 | 一种氟马西尼的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1143728A (en) | 1979-10-04 | 1983-03-29 | Max Gerecke | Imidazodiazepine derivatives |
| IL74070A (en) | 1984-01-19 | 1988-12-30 | Hoffmann La Roche | Imidazodiazepine derivatives,their manufacture and pharmaceutical compositions containing them |
| DK174086D0 (da) | 1986-04-16 | 1986-04-16 | Ferrosan As | Nye benzodiazepinderivater samt fremgangsmaade til fremstilling af samme |
| US4897392A (en) | 1989-07-03 | 1990-01-30 | Hoechst-Roussel Pharmaceuticals, Inc. | 4H-indolo(1,2-d)(1,2,4)triazolo(4,3-A)(1,4)benzodiazepines |
| TW201311B (es) * | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| TWI239333B (en) * | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
-
2005
- 2005-10-04 RU RU2007112675/15A patent/RU2007112675A/ru not_active Application Discontinuation
- 2005-10-04 EP EP05797208A patent/EP1809297B1/en not_active Expired - Lifetime
- 2005-10-04 BR BRPI0517412-0A patent/BRPI0517412A/pt not_active IP Right Cessation
- 2005-10-04 DE DE602005008633T patent/DE602005008633D1/de not_active Expired - Lifetime
- 2005-10-04 AT AT05797208T patent/ATE402707T1/de active
- 2005-10-04 CN CN2005800348517A patent/CN101039678B/zh not_active Expired - Fee Related
- 2005-10-04 KR KR1020077008246A patent/KR100869388B1/ko not_active Expired - Fee Related
- 2005-10-04 MX MX2007004250A patent/MX2007004250A/es active IP Right Grant
- 2005-10-04 WO PCT/EP2005/010655 patent/WO2006040038A1/en not_active Ceased
- 2005-10-04 CA CA002581918A patent/CA2581918A1/en not_active Abandoned
- 2005-10-04 JP JP2007536039A patent/JP5117192B2/ja not_active Expired - Fee Related
- 2005-10-04 ES ES05797208T patent/ES2312022T3/es not_active Expired - Lifetime
- 2005-10-04 AU AU2005293820A patent/AU2005293820B2/en not_active Ceased
- 2005-10-07 US US11/245,736 patent/US7671048B2/en not_active Expired - Fee Related
-
2009
- 2009-11-16 US US12/618,802 patent/US8293730B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005293820B2 (en) | 2010-11-25 |
| CA2581918A1 (en) | 2006-04-20 |
| BRPI0517412A (pt) | 2008-10-07 |
| US20100075954A1 (en) | 2010-03-25 |
| AU2005293820A1 (en) | 2006-04-20 |
| ES2312022T3 (es) | 2009-02-16 |
| US20060079507A1 (en) | 2006-04-13 |
| CN101039678B (zh) | 2011-06-15 |
| CN101039678A (zh) | 2007-09-19 |
| ATE402707T1 (de) | 2008-08-15 |
| JP2008515941A (ja) | 2008-05-15 |
| EP1809297A1 (en) | 2007-07-25 |
| US7671048B2 (en) | 2010-03-02 |
| DE602005008633D1 (de) | 2008-09-11 |
| US8293730B2 (en) | 2012-10-23 |
| KR20070053324A (ko) | 2007-05-23 |
| WO2006040038A1 (en) | 2006-04-20 |
| RU2007112675A (ru) | 2008-11-20 |
| KR100869388B1 (ko) | 2008-11-21 |
| JP5117192B2 (ja) | 2013-01-09 |
| EP1809297B1 (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007004250A (es) | Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos. | |
| CA2401229A1 (en) | Aryl fused azapolycyclic compounds | |
| MXPA06000716A (es) | Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1. | |
| HUP0402336A2 (hu) | Tieno[2,3-d]pirimidin-2,4-dion-származékok, eljárás előállításukra, alkalmazásuk autoimmun betegségek modulálására és a vegyületeket tartalmazó gyógyszerkészítmények | |
| TW200505907A (en) | Piperidine-benzenesulfonamide derivatives | |
| MY118163A (en) | Aryl fused azapolycyclic compounds | |
| SE0104332D0 (sv) | Therapeutic agents | |
| DE60106641D1 (de) | Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten | |
| NO20072046L (no) | Halogensubstituerte benzodiazepinderivater | |
| WO2007143523A3 (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| ATE348101T1 (de) | Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion | |
| WO2006068954A3 (en) | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | |
| MXPA05014201A (es) | Pirazolo [3,4-b] piridin-6-onas como inhibidores de la gsk-3. | |
| MXPA05013628A (es) | Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3. | |
| TW200630372A (en) | Imidazo-benzodiazepine derivatives | |
| YU64400A (sh) | Aril fuzirana azapoliciklična jedinjenja | |
| CA2375671A1 (en) | 4-phenyl-pyrimidine derivatives | |
| WO2002042280A3 (en) | Pyrimidine derivatives | |
| MXPA02011464A (es) | Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1. | |
| TW200631953A (en) | Tetracyclic imidazo-benzodiazepines | |
| MXPA04003278A (es) | Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina. | |
| DE60111553D1 (de) | Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen | |
| MXPA04001201A (es) | Derivados tetraciclicos de indol como ligandos del receptor de 5-ht. | |
| WO2005007630A3 (en) | Aryl fused azapolycyclic compounds | |
| MXPA04008880A (es) | Nuevos compuestos de benzoindolina, un proceso para su preparacion y las composiciones farmaceuticals que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |